Targeting B7-H3 with TriKEs to treat metastatic prostate cancer

Who could benefit from this research

What this research studies

This grant supports developing a trispecific killer engager (TriKE) that enhances NK cell activity against prostate cancer by targeting B7-H3 and providing IL-15–based stimulation. The approach builds on years of NK cell therapy research and aims to extend benefits beyond blood cancers into solid tumors like metastatic castration-resistant prostate cancer. If successful, it could offer a new, targeted patient treatment that mobilizes the body's own immune cells with potentially fewer side effects than conventional therapies.

Why it matters

Where this research is happening

• Mayo Clinic Rochester
  Rochester, United States Active

Researchers

• Principal investigator: Miller, Jeffrey S. — Mayo Clinic Rochester
• Study coordinator: Miller, Jeffrey S.

Related research

Other NIH-funded projects on the same topics.

• Understanding how aggressive cell states emerge in castration-resistant prostate cancer

  A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11463275

• Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer

  Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.

  NIH research University of Maryland Baltimore · Baltimore, United States · NIH-11452128

• Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer

  Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11427360

• Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy

  This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11419184

• Hyperactive methylation in a hard-to-treat prostate cancer subtype

  Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415138

• Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer

  A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11411377

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.